CAPECITABINE-D11

Description

Capecitabine-d₁₁ is intended for use as an internal standard for the quantification of capecitabine by GC- or LC-MS. Capecitabine is a prodrug form of 5-fluorouracil (5-FU). It is converted to 5-FU via several enzymatic steps beginning in the liver and ending with conversion in tumor tissue by thymidine phosphorylase, an enzyme that is more concentrated in tumor tissue compared with normal tissue. Capecitabine is cytotoxic only at high concentrations in Scaber, SIHA, and MKN45 cells (IC₅₀s = 97, 578, and 994 μM, respectively) and is inactive in a variety of cancer cell lines, including COLO 205, HCT116, and MCF-7 cells (IC₅₀s = >1,000 μM).

Chemical Properties

Off-White Powder

Uses

Capecitabine D11 is an isotopically labelled antineoplastic agent. A prodrug of Doxifluridine.;Labeled Capecitabine, intended for use as an internal standard for the quantification of Capecitabine by GC- or LC-mass spectrometry.

Uses

An isotopically labelled antineoplastic agent. A prodrug of Doxifluridine (D556750).

References

[1] M MIWA. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J]. European Journal of Cancer, 1998, 34 8: Pages 1274-1281. DOI: 10.1016/s0959-8049(98)00058-6